Business
Bruker Announces New Results in Deep, Unbiased Plasma Proteomics, PaSER 1.1 Software and New Cross-linking Consumables at US HUPO 2021
Roman Fischer of Oxford University demonstrates high-throughput 4D proteomics on non-depleted, untreated plasma identifying >350 protein groups with short
About this update from Bruker Corporation
[{"type":"text","content":"\n\nRoman Fischer of Oxford University demonstrates high-throughput 4D proteomics on non-depleted, untreated plasma identifying >350 protein groups with short 10-20 minute methods, enabling high throughput, robust biomarker discovery\n\n\nOmicEra Diagnostics reports running 720 undepleted serum samples from 31 COVID-19 patients over just 12 days on a single timsTOF Pro system at a rate of 60 samples/day, with 502 proteins quantified and 116 proteins with significant changes in expression levels\n\n\nTIMS/PASEF processing of plasma samples with the Seer Proteograph™ Product Suite yields unprecedented depth, speed, and scalability, with the identification of >1,700 protein groups \n\n\nPaSER software version 1.1 released, including performance enhancements and visualization of Mobility-Offset Mass-Aligned (MOMA) analysis in 4D proteomics\n\n\nEnrichable PhoX cross-linker and three cleavable cross-linkers launched, analysis of timsTOF cross-linking data to be supported in MaxQuant and XlinkX for structural proteomics and protein-protein interaction (PPI) research\n\n\n BILLERICA, Mass.--(BUSINESS WIRE)--\nAt the virtual 17th US HUPO Conference (US HUPO 2021), Bruker Corporation (Nasdaq: BRKR) today announces progress with several collaborations in deep, unbiased plasma proteomics, leveraging the speed, sensitivity and dynamic range of 4D proteomics on timsTOF Pro systems.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005537/en/Fig 1: Large-scale peptide CCS measurement with TIMS and PASEF. www.nature.com/articles/s41467-021-21352-8 (Photo: Business Wire)\nNew results from a key collaborator, Professor Kirk Hansen of the University of Colorado Anschutz Medical Center, will be presented at Bruker’s virtual seminar at US HUPO on Tuesday, March 9th at 2:00 p.m. EST. Registration for the US HUPO Conference is required to attend the event live. Dr. Hansen will present studies of the plasma proteomes of patients infected with COVID-19, as well as a large-cohort comparison of plasma proteome changes in trauma patients.\n\nDr. Hansen’s research reveals protein dynamics in acute injury and disease states with tens of thousands of measurements per sample. Running larger clinical cohorts is illuminating molecular relationships and mechanistic understanding that has the poten...